新技术:THRIVE序列用于颅内动脉瘤血管内治疗后的随访
回顾性连续病例系列在3T MRI上对50例患者66个血管内治疗的颅内动脉瘤行3D TOF-MRA、THRIVE和CE-MRA检查,以CE-MRA为参考标准按Raymond标准分级;THRIVE与CE-MRA总体符合61/66(92.42%)、κ=0.800,TOF与CE-MRA符合54/66(81.8%)、κ=0.502;THRIVE敏感度77.8%、特异度97.9%,TOF敏感度44.4%、特异度97.9%。
要点
- THRIVE与CE-MRA总体符合61/66(92.42%),κ=0.800(p<0.001)。
- TOF与CE-MRA总体符合54/66(81.8%),κ=0.502(p<0.001)。
- 以CE-MRA为参考,THRIVE敏感度77.8%、特异度97.9%。
核心结论
- THRIVE序列可作为无对比剂方法用于颅内动脉瘤血管内治疗后的监测。
研究设计与样本
- 回顾性连续病例系列,纳入50例患者66个血管内治疗的颅内动脉瘤,行3T MR随访。
- 3D TOF-MRA与THRIVE为指标试验,CE-MRA为参考标准。
- 采用MIP技术按Raymond标准将源图像分为class 1、class 2和class 3。
关键影像表现/征象
- 原文未报告影像征象。
诊断标准与关键数值
- 按Raymond标准分级:class 1、class 2、class 3。
- THRIVE与CE-MRA符合61/66(92.42%),κ=0.800(p<0.001)。
- TOF与CE-MRA符合54/66(81.8%),κ=0.502(p<0.001)。
- 以CE-MRA为参考标准,TOF敏感度44.4%、特异度97.9%。
- 以CE-MRA为参考标准,THRIVE敏感度77.8%、特异度97.9%。
临床应用与阅片要点
- 作者认为THRIVE序列可作为无对比剂方法用于颅内动脉瘤血管内治疗后的监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine the diagnostic accuracy of 3D time of flight MR angiography (TOF-MRA), contrast enhanced MR angiography (CE-MRA), and T1-weighted high-resolution isotropic volume examination (THRIVE) at 3 T for the evaluation of intracranial aneurysm occlusion after endovascular treatment and to evaluate the usability of the THRIVE sequence in endovascular treatment follow-up.
METHODS: In 3 T MR follow-up examinations of 66 aneurysms in 50 patients treated endovascularly, 3D TOF-MRA (index test), THRIVE (index test), and CE-MRA (reference standard) examinations were performed in a retrospective consecutive case series. Source images were classified as class 1, class 2, and class 3 according to the Raymond criteria using MIP (maximum intensity projection) techniques. The compatibility between sequences was evaluated with the Kappa test. The sensitivity and specificity were also calculated.
RESULTS: In the evaluation of THRIVE and CE-MRA sequences, compatibility was determined in 61 cases in total, with an overall fit of 61/66 (92.42%). A statistically significant correlation was found between THRIVE and CE-MRA (p < 0.001, κ = 0.800). In the evaluation of TOF and CE-MRA sequences, compatibility was determined in 54 cases in total, and the overall fit was 54/66 (81.8%). A statistically significant agreement was found between TOF and CE-MRA (p < 0.001, κ = 0.502). Assuming that CE-MRA is a reference standard, the sensitivity and specificity of the TOF sequence were 44.4% and 97.9%, respectively, and the sensitivity and specificity of the THRIVE sequence were 77.8% and 97.9%, respectively.
CONCLUSION: The THRIVE sequence can be used as a noncontrast method for monitoring endovascularly treated intracranial aneurysms.
引用
- Mırçık E, Hakyemez B. New technique: the use of the THRIVE sequence in the follow-up of patients who received endovascular intracranial aneurysm treatment. Neuroradiology. 2020. PMID: 32914366. doi:10.1007/s00234-020-02527-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。